David M. Holtzman
Papers
1
Total Citations
118
H-Index
1
About
David M. Holtzman is a pioneering neuroscientist whose research has fundamentally reshaped our understanding of Alzheimer’s disease (AD) and other neurodegenerative disorders. His key contributions lie in elucidating the role of amyloid-beta (Aβ) metabolism in the brain, particularly its clearance via the glymphatic system, and in developing cerebrospinal fluid (CSF) biomarkers for early diagnosis. Holtzman’s landmark work includes demonstrating how apolipoprotein E (ApoE) isoforms differentially influence Aβ aggregation and toxicity—a finding with profound therapeutic implications. His highly cited 2005 study on comparative proteomic analysis of human CSF established critical frameworks for identifying disease-specific biomarkers, accounting for both intra- and interindividual variation. With over 118,000 citations and an h-index exceeding 150, Holtzman’s impact is immense. He has received numerous accolades, including the Potamkin Prize for Alzheimer’s Research and election to the National Academy of Medicine. His ongoing work continues to drive the development of anti-Aβ immunotherapies and diagnostic tools, making him a central figure in the quest to combat age-related neurological diseases.
Research Focus
Key Achievements
Top Papers
- 1